An observational study in Ischemic Heart Disease and Heart Failure, sponsored by Federico II University. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-07.
Sponsored by Federico II University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies in Myocardial Ischemia with a site in Italy — 15 open to participants now, 25 under way, none of them phase 3. Myocardial Ischemia · Italy.
Among the 87 studies in Myocardial Ischemia with a site in Italy, this one is the 20th largest by planned enrollment of the 37 observational ones that give a count, is one of 5 that started in 2024, is one of 37 observational ones, reaches primary completion later than 5 of the 24 other live ones, and was the 82nd registered.
1,123 studies on the registry are indexed under Myocardial Ischemia; 177 are open to participants now.
Browse Myocardial Ischemia studies →15 of the 87 studies in Myocardial Ischemia with a site in Italy are open now. Recruiting first, the newest first:
IRCCS San Raffaele · Sites in Italy
Ages 18+
Fondazione Ricerca e Innovazione Cardiovascolare ETS · Sites in Italy
IRCCS Policlinico S. Donato · Sites in Italy
Ages 16+ · Healthy volunteers
Federico II University · Sites in Italy
IRCCS Policlinico S. Donato · Sites in Italy
Ages 6+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 135 Myocardial Ischemia studies recruiting now, 92 (68%) set no upper age limit and 6 (4%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 8 · Phase 4 13
First in 2002; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 450 is above the median of 318 across 398 observational studies indexed under Myocardial Ischemia.
Median enrollment 418 across the 49 interventional studies, 509 across the 37 observational. Of the 45 that completed or were terminated, 6 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 87 have an industry lead sponsor. The 10 most frequent:
Federico II University is the lead sponsor of 366 studies on the registry; 60 are open to participants now.
Federico II University has 5 studies filed under Myocardial Ischemia — fewer than ten, so there is no comparison to draw.
7 of the studies in Myocardial Ischemia with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04604782GE HealthcareA Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients | 2026-12 |
| NCT06309511Istituto Auxologico ItalianoSubendocardial Viability Ratio in Hypertension | 2026-12-31 |
| NCT05027984Centro per la Lotta Contro l'Infarto - Fondazione OnlusInterventional Strategy for Non-culprit Lesions With Major Vulnerability Criteria at OCT in Patients With ACS | 2027-01-31 |
| NCT07095634IRCCS Policlinico S. DonatoEstimation of Cardiovascular Risk in Patients With Crohn's Disease and Ulcerative Colitis (PROVACI) | 2027-02 |
| NCT06705751IRCCS Policlinico S. DonatoSpeed-up the Diagnosis and Evaluation of anoMalous Coronary ARTery From the Aorta | 2027-02 |
Add all 7 to your calendar (.ics) → With an account.
Among the 87 studies in Myocardial Ischemia with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, non-randomized, single center, open label clinical study enrolling patients affected by 1) chronic ischemic heart disease with evidence or suspect significant myocardial ischemia (group 1, CCS) or 2) acute coronary syndromes (group 2, ACS), both undergoing coronary angiography and eventually coronary revascularization at the Department of Scienze Cardiovascolari, Diagnostica per Immagini ed Emergenze Cardiovascolari of Federico II University Hospital, Naples, Italy. Age and sex-matched healthy volunteers without known ischemic heart disease (group 3, Ctr) will also be included as a control group. At enrollment (time 0), and after 48 hours (time 48 h), 1 month (time 1mo) and 6 month-follow-up visits (time 6 mo), clinical evaluation, ECG, trans-thoracic echocardiography and blood sampling will be performed, to isolate peripheral blood mononuclear cells (PBMC) and perform standard blood tests. The enrolment phase will last 24 months, and will likely involve 450 patients distributed as follows, according to the number of patients annually referring to our University
Hospital:
This is a prospective, non-randomized, single center, open label clinical study enrolling patients affected by 1) chronic ischemic heart disease with evidence or suspect significant myocardial ischemia (group 1, CCS) or 2) acute coronary syndromes (group 2, ACS), both undergoing coronary angiography and eventually coronary revascularization at the Department of Scienze Cardiovascolari, Diagnostica per Immagini ed Emergenze Cardiovascolari of Federico II University Hospital, Naples, Italy. Age and sex-matched healthy volunteers without known ischemic heart disease (group 3, Ctr) will also be included as a control group. At enrollment (time 0), and after 48 hours (time 48 h), 1 month (time 1mo) and 6 month-follow-up visits (time 6 mo), clinical evaluation, ECG, trans-thoracic echocardiography and blood sampling will be performed, to isolate peripheral blood mononuclear cells (PBMC) and perform standard blood tests.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Group 1:
History (> 6 months) of ischemic heart disease (prior myocardial infarction, prior percutaneous coronary intervention, prior surgical revascularization) and clinical or imaging evidence of chronic moderate or severe myocardial ischemia
Group 2:
Patients with acute coronary syndromes at presentation including ST-elevation myocardial infarction, Non-ST elevation myocardial infarction, and unstable angina.
Group 3:
Healthy volunteers with no prior history of ischemic heart disease or clinical/imaging evidence of myocardial ischemia.
Exclusion Criteria:
Patients unwilling to provide to participate to the study
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Blood sampling
Other: Blood sampling
Other: Blood sampling
blood sampling from peripheral vein
Left ventricular ejection fraction
Time frame: 0, 1 month, 6 months
NT-pro-BNP levels
Time frame: 0, 1 month, 6 months
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2024 (actual). Primary completion is estimated for Aug 2025, 17 months after the start.
Of 165 non-industry observational studies under Myocardial Ischemia, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 127. This study's planned 17 months is below that.
Counting every sponsor, half of 204 studies reached it within 40 months; a quarter within 21 and three quarters within 90.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.